Immunovant, Inc.
NASDAQ:IMVTBiotechnology
+$0.69 today
- Market cap
- $6.86B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
Volume 0.91M
Average 1.84M
IMVT Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Immunovant, Inc.NASDAQ: IMVT
Operating Expenses · Q2 FY2027 · quarter ended Sep 2026
Operating expenses dips below year-ago levels
Q2 FY2027 operating expenses of $104.16M fell 21.0% year over year, behind the +10.5% change in trailing-twelve-month operating expenses. Sequentially, it fell 35.0% from the prior quarter. Over 3 fiscal years it compounded at +36.8% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -21.0% toward the trailing-twelve-month pace of +10.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2026
- 532.9M USD
- Year-over-year change
- +21.6%
- 4-year CAGR
- +35.9%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 532.9M | +21.6% |
| FY2025 | 2025-03-31 | 438.15M | +62.2% |
| FY2024 | 2024-03-31 | 270.21M | +29.7% |
| FY2023 | 2023-03-31 | 208.28M | +33.5% |
| FY2022 | 2022-03-31 | 156.03M | — |
Operating Expenses vs competitors
How IMVT compares with its peers on the latest reported figures
- IMVT's LTM Sep 2026 operating expenses of $538.39M is the 2nd highest of the 11 companies compared; the peer median is $191.28M.
- Its year-over-year change of +10.5% is the 8th highest of 11, against a peer median of +24.4%.
- Operating expenses amounts to 7588.4% of revenue for IMVT, versus a peer median of 80.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $549.98M | +56.6% | +21.1% | 61.3% | |
| LTM Sep 2026 | $538.39M | +10.5% | +36.8% | 7588.4% | |
| LTM Mar 2026 | $319.32M | +163.2% | +148.0% | — | |
| LTM Mar 2026 | $240.35M | +15.1% | — | — | |
| LTM Mar 2026 | $229.74M | +420.0% | +71.3% | 98.9% | |
| LTM Mar 2026 | $203.15M | +11.1% | +13.5% | — | |
| LTM Mar 2026 | $179.4M | +33.6% | +47.1% | — | |
| LTM Mar 2026 | $109.61M | +8.6% | -4.8% | — | |
| LTM Mar 2026 | $86.87M | -40.0% | -8.6% | 1038.2% | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $39.39M | +37.0% | — | — |
| LTM Mar 2026 | $32.06M | -49.4% | -7.4% | 59.7% | |
| Peer median (excluding IMVT) | $191.28M | +24.4% | +17.3% | 80.1% | |
Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 101.81M | 160.26M | 212.93M | 360.92M | 456.66M |
| Selling, General & Admin | 54.23M | 48.02M | 57.28M | 77.24M | 76.24M |
| Operating Expenses | 156.03M | 208.28M | 270.21M | 438.15M | 532.9M |
| Depreciation & Amortization | 126K | 193K | 231K | 377K | 409K |
| EBITDA | (156.69M) | (198.28M) | (258.54M) | (412.57M) | (504.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (156.03M) | (208.28M) | (270.21M) | (438.15M) | (532.9M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 7.58M | 24.95M | 24.73M | 25.33M |
| Interest Expense | 0 | 12.48M | 0 | 0 | 0 |
| Other Income / Expenses | (781K) | (2.68M) | 11.44M | 25.2M | 27.51M |
| Income Before Tax | (156.81M) | (210.95M) | (258.77M) | (412.95M) | (505.39M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (84K) | 9K | 567K | 891K | 215K |
| Net Income | (156.73M) | (210.96M) | (259.34M) | (413.84M) | (505.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| EPS (Diluted) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| Weighted Avg Shares | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
| Weighted Avg Shares (Diluted) | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
Immunovant, Inc.
NASDAQ:IMVT
Intrinsic Alpha fair value
Locked
Current Price
$33.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.